FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3133256211> ?p ?o ?g. }

• W3133256211 abstract "Abstract Background Hetrombopag, a novel thrombopoietin receptor agonist, has been found in phase I studies to increase platelet counts and reduce bleeding risks in adults with immune thrombocytopenia (ITP). This phase III study aimed to evaluate the efficacy and safety of hetrombopag in ITP patients. Methods Patients who had not responded to or had relapsed after previous treatment were treated with an initial dosage of once-daily 2.5 or 5 mg hetrombopag (defined as the HETROM-2.5 or HETROM-5 group) or with matching placebo in a randomized, double-blind, 10-week treatment period. Patients who received placebo and completed 10 weeks of treatment switched to receive eltrombopag, and patients treated with hetrombopag in the double-blind period continued hetrombopag during the following open-label 14-week treatment. The primary endpoint was the proportion of responders (defined as those achieving a platelet count of ≥ 50 × 10 9 /L) after 8 weeks of treatment. Results The primary endpoint was achieved by significantly more patients in the HETROM-2.5 (58.9%; odds ratio [OR] 25.97, 95% confidence interval [CI] 9.83–68.63; p < 0.0001) and HETROM-5 (64.3%; OR 32.81, 95% CI 12.39–86.87; p < 0.0001) group than in the Placebo group (5.9%). Hetrombopag was also superior to placebo in achieving a platelet response and in reducing the bleeding risk and use of rescue therapy throughout 8 weeks of treatment. The durable platelet response to hetrombopag was maintained throughout 24 weeks. The most common adverse events were upper respiratory tract infection (42.2%), urinary tract infection (17.1%), immune thrombocytopenic purpura (17.1%) and hematuria (15%) with 24-week hetrombopag treatment. Conclusions In ITP patients, hetrombopag is efficacious and well tolerated with a manageable safety profile. Trial registration Clinical trials.gov NCT03222843 , registered July 19, 2017, retrospectively registered." @default.
• W3133256211 created "2021-03-01" @default.
• W3133256211 creator A5000239300 @default.
• W3133256211 creator A5013508493 @default.
• W3133256211 creator A5013718591 @default.
• W3133256211 creator A5016406818 @default.
• W3133256211 creator A5016524884 @default.
• W3133256211 creator A5016780203 @default.
• W3133256211 creator A5023342846 @default.
• W3133256211 creator A5024604872 @default.
• W3133256211 creator A5028939393 @default.
• W3133256211 creator A5029667848 @default.
• W3133256211 creator A5035282947 @default.
• W3133256211 creator A5036581174 @default.
• W3133256211 creator A5038805449 @default.
• W3133256211 creator A5045714102 @default.
• W3133256211 creator A5048815633 @default.
• W3133256211 creator A5048888033 @default.
• W3133256211 creator A5051832254 @default.
• W3133256211 creator A5053307277 @default.
• W3133256211 creator A5057401157 @default.
• W3133256211 creator A5062652934 @default.
• W3133256211 creator A5063481044 @default.
• W3133256211 creator A5066047367 @default.
• W3133256211 creator A5067997175 @default.
• W3133256211 creator A5068477112 @default.
• W3133256211 creator A5068729755 @default.
• W3133256211 creator A5074069807 @default.
• W3133256211 creator A5077384746 @default.
• W3133256211 creator A5077554678 @default.
• W3133256211 creator A5077666079 @default.
• W3133256211 creator A5080468117 @default.
• W3133256211 creator A5080945746 @default.
• W3133256211 creator A5086502740 @default.
• W3133256211 creator A5086720717 @default.
• W3133256211 creator A5088192232 @default.
• W3133256211 creator A5089427194 @default.
• W3133256211 creator A5090567341 @default.
• W3133256211 creator A5090888787 @default.
• W3133256211 creator A5091815974 @default.
• W3133256211 date "2021-02-25" @default.
• W3133256211 modified "2023-10-12" @default.
• W3133256211 title "A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia" @default.
• W3133256211 cites W1531484155 @default.
• W3133256211 cites W1964908644 @default.
• W3133256211 cites W1970837685 @default.
• W3133256211 cites W1977058832 @default.
• W3133256211 cites W1980002878 @default.
• W3133256211 cites W1981232641 @default.
• W3133256211 cites W1984073642 @default.
• W3133256211 cites W1991612682 @default.
• W3133256211 cites W2003391236 @default.
• W3133256211 cites W2010176345 @default.
• W3133256211 cites W2013946336 @default.
• W3133256211 cites W2014207233 @default.
• W3133256211 cites W2035185745 @default.
• W3133256211 cites W2109372372 @default.
• W3133256211 cites W2145439228 @default.
• W3133256211 cites W2156817733 @default.
• W3133256211 cites W2204521850 @default.
• W3133256211 cites W2414381444 @default.
• W3133256211 cites W2514684873 @default.
• W3133256211 cites W2531180061 @default.
• W3133256211 cites W2586463853 @default.
• W3133256211 cites W2606110133 @default.
• W3133256211 cites W2795668706 @default.
• W3133256211 cites W2804273416 @default.
• W3133256211 cites W2889546509 @default.
• W3133256211 cites W2891044782 @default.
• W3133256211 cites W2943930531 @default.
• W3133256211 cites W2944617176 @default.
• W3133256211 cites W2947784516 @default.
• W3133256211 cites W2993666578 @default.
• W3133256211 cites W4211106014 @default.
• W3133256211 doi "https://doi.org/10.1186/s13045-021-01047-9" @default.
• W3133256211 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7905908" @default.
• W3133256211 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33632264" @default.
• W3133256211 hasPublicationYear "2021" @default.
• W3133256211 type Work @default.
• W3133256211 sameAs 3133256211 @default.
• W3133256211 citedByCount "26" @default.
• W3133256211 countsByYear W31332562112021 @default.
• W3133256211 countsByYear W31332562112022 @default.
• W3133256211 countsByYear W31332562112023 @default.
• W3133256211 crossrefType "journal-article" @default.
• W3133256211 hasAuthorship W3133256211A5000239300 @default.
• W3133256211 hasAuthorship W3133256211A5013508493 @default.
• W3133256211 hasAuthorship W3133256211A5013718591 @default.
• W3133256211 hasAuthorship W3133256211A5016406818 @default.
• W3133256211 hasAuthorship W3133256211A5016524884 @default.
• W3133256211 hasAuthorship W3133256211A5016780203 @default.
• W3133256211 hasAuthorship W3133256211A5023342846 @default.
• W3133256211 hasAuthorship W3133256211A5024604872 @default.
• W3133256211 hasAuthorship W3133256211A5028939393 @default.
• W3133256211 hasAuthorship W3133256211A5029667848 @default.
• W3133256211 hasAuthorship W3133256211A5035282947 @default.
• W3133256211 hasAuthorship W3133256211A5036581174 @default.
• W3133256211 hasAuthorship W3133256211A5038805449 @default.
• W3133256211 hasAuthorship W3133256211A5045714102 @default.
• W3133256211 hasAuthorship W3133256211A5048815633 @default.

• next